DELFI Diagnostics’ Blood Test Validated for Early Lung Cancer Detection
DELFI’s blood-based Lung test has been clinically validated to enhance early detection of lung cancer, demonstrating high sensitivity.
Read MorePosted by Andy Lundin | Jun 3, 2024 | Lung Cancer |
DELFI’s blood-based Lung test has been clinically validated to enhance early detection of lung cancer, demonstrating high sensitivity.
Read MorePosted by Andy Lundin | May 13, 2024 | Lung Cancer |
OSF HealthCare will use DELFI’s FirstLook Lung blood test to enhance lung cancer screening rates and early detection efforts.
Read MorePosted by Andy Lundin | Apr 16, 2024 | Lung Cancer |
CAP developed recommendations for testing immunotherapy biomarkers, such as PD-L1 and TM), in patients with NSCLC.
Read MorePosted by Andy Lundin | Apr 4, 2024 | Lung Cancer |
Nucleix will present data that demonstrates the potential of a PCR assay to accurately differentiate between small cell lung cancer subtypes.
Read MorePosted by Andy Lundin | Jan 23, 2024 | Lung Cancer |
New noninvasive diagnostic solutions for lung cancer being developed function as a complement to LDCT imaging.
Read More